ASH 2022 | Key updates in MDS from ASH on magrolimab, sabatolimab, venetoclax & tamibarotene
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, comments on some of the highlights in myelodysplastic syndromes (MDS) presented at ASH 2022. Dr Sallman first comments on magrolimab and sabatolimab, two key agents currently being evaluated in pivotal Phase III trials, and then discusses the VERONA (NCT04401748) and STIMULUS-MDS1 (NCT03946670) trials. Dr Sallman also highlights the retinoic acid receptor alpha (RARα) agonist tamibarotene and notes that the future will likely focus on novel triplet combinations. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Incyte: Speakers Bureau; Syndax: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Intellia: Membership on an entity’s Board of Directors or advisory committees; BMS: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Agios: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Syntrix Pharmaceuticals: Research Funding; Lixte: Patents & Royalties: LB-100; Nemucore: Membership on an entity’s Board of Directors or advisory committees
